Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

Also called NCT04488978

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 440 participants (enrolled count) (from the registry)
Sponsor
  • Handok Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04488978
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04488978. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-21 (actual); primary completion 2021-11-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
Condition
Essential Hypertension
Intervention (Drug)
Irbesartan/Amlodipine
Lead sponsor
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct04488978
Content hash
9a8d3b2d8282397bab90316ccfcbe2d3f927fa73af08e9812361dac364b730a2